Exeliom Biosciences is developing a new generation of immunotherapies based on therapeutic targets that play a critical role in our innate immunity.

Our lead candidate, EXL01, is being currently evaluated in a Phase 1 clinical trial in Crohn’s disease, and in two Phase 2 clinical trials in gastric cancer in combination with FOLFOX and nivolumab, and in the prevention of recurrent C. difficile infection as an alternative to FMT. At least three additional Phase 2 trials in immune-oncology in combination with immune-checkpoint inhibitors and in postoperative Crohn’s disease are expected to start this year.

EXL01, a single-strain (F. prausnitzii) live biotherapeutic product, carries unique effectors promoting a distinct and potent immuno-modulatory signal. EXL01 also promotes antitumor efficacy of PD-L1 therapy and can be used in combination with immune-checkpoint inhibitors.
Exeliom is pushing in parallel other candidates in its pipeline, including small molecules, acting on essential pathways of our innate immunity.

Our lead candidate, EXL01, has unique effectors that can co-activate key targets in the innate immune response to induce tolerogenic effects without inhibiting the immune system. As a potent immunomodulator, EXL01 is more suitable for chronic administration than existing immunosuppressants currently on the market, particularly for the treatment of inflammatory bowel diseases. Interestingly, the tolerogenic effects induced by EXL01 on the innate immune system have a boosting effect on immunotherapies when administered in combination, notably in immuno-oncology. Indeed, EXL01 enables better expression of immune checkpoint receptors and therefore better target presentation for immune checkpoint inhibitors.

–  Therapeutic areas: Immuno-Oncology, Inflammatory Bowel Diseases, Infectious Diseases

–  Based in: Paris, Jouy-en-Josas, Dijon (FRANCE)

–  Employees: 1 – 10

– Created in: 2016